Centre for Genomic Pathogen Surveillance

What Centre for Genomic Pathogen Surveillance does

The Centre for Genomic Pathogen Surveillance is a privately held, for-profit entity founded in 2015 and headquartered in Oxford, United Kingdom, with a headcount of 11–50 employees. According to its stated profile, the organization provides surveillance strategies, analysis, and training aimed at tackling antimicrobial resistance (AMR), positioning it within the global health and infectious-disease genomics domain. Its functional focus spans three service layers: designing surveillance approaches (likely for public-health and clinical stakeholders), conducting genomic analysis of pathogens (implying bioinformatics and sequencing-data workflows), and delivering training (capacity building for partner institutions).

The business model is not explicitly disclosed in the available source material. Given the small headcount, Oxford-based research-adjacent footprint, and the public-good nature of AMR surveillance, revenue mechanics are likely a mix of grants, government/public-health contracts, and paid training engagements rather than a high-volume commercial product model. The company maintains a website at pathogensurveillance.net, but at the time of source capture the page was behind a verification/loading screen, so deeper product detail, customer references, partnership disclosures, and pricing signals were not retrievable. There is no evidence in the input data of productized software, SaaS offerings, named customers, or geographic footprint beyond the Oxford HQ.

As a result, this description is intentionally constrained to the few firmographic and stated-scope facts available; further diligence (e.g., direct site crawl, Companies House filings, grant databases, publication record) would be required to substantiate technical architecture, GTM, and commercial traction.

Name

Centre for Genomic Pathogen Surveillance

Website

https://pathogensurveillance.net

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

11–50 employees

Short description

Centre for Genomic Pathogen Surveillance is an Oxford-based, privately held firm (founded 2015, 11–50 employees) that provides surveillance strategies, genomic analysis, and training to help public-health and clinical stakeholders tackle antimicrobial resistance.

Ownership category

akta.pro rank

Product category

Genomic Pathogen Surveillance Services

NAICS

Medical and Diagnostic Laboratories (6215), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Medical Laboratories (8071), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Laboratory-Based Surveillance & Genomic Epidemiology (WGS/NGS) (HLAJABAC)

akta.pro secondary industries

Healthcare-Associated Infection (HAI) & Antimicrobial Resistance (AMR) Surveillance (HLAJABAH), Antimicrobial Resistance (AMR) & Antibiotic Susceptibility Reference Networks (HLAJAIAF), Microbiology & Infectious Disease Diagnostics (Culture/ID/AST) (HLAHAAAC)

Keywords

• Genomic pathogen surveillance
• Antimicrobial resistance analysis
• Pathogen genomics services
• Infectious disease surveillance
• Genomics training programmes

Headquarters

HQ city

Oxford

HQ country

United Kingdom

HQ region

Europe

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations

Core offering

Centre for Genomic Pathogen Surveillance provides surveillance strategies, analysis, and training to tackle antimicrobial resistance. The organisation combines genomic data analysis with strategic advisory and capacity-building services for stakeholders working on infectious disease surveillance and AMR mitigation.

Differentiator

Problem solved

Functional benefit

Products and services

• Surveillance strategy consulting Design and advisory service that helps research and public-health institutions develop genomic surveillance strategies aimed at tackling antimicrobial resistance.
• Genomic analysis services Analytical service that interprets pathogen genomic data to characterise antimicrobial resistance patterns and inform surveillance efforts, delivered to institutional clients in research and public health.
• Training programmes in genomic surveillance Capacity-building training programmes that teach research and public-health staff the methods and applied practices of genomic surveillance for antimicrobial resistance.

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Recent moves1 record

Broad incumbents

• Illumina: A leading sequencing technology vendor whose platforms underpin most genomic epidemiology and AMR surveillance globally. Its push into pathogen WGS and bioinformatics offerings (e.g., Illumina base space, Epi2me) makes it an adjacent incumbent shaping the same market.
• bioMérieux: A global microbiology and infectious disease diagnostics company whose AMR surveillance offerings (including the BIOBALL reference standards and microbiology IT) overlap the Centre's antimicrobial resistance surveillance remit at a much larger scale.
• Quadram Institute Bioscience: A UK food and health research institute with a strong track record in pathogen genomics, AMR and outbreak surveillance — closely comparable to the Centre in terms of scientific remit but operating at much larger institutional scale.
• Oxford Nanopore Technologies: A Oxford-based sequencing platform vendor whose technology underpins a large share of real-time pathogen WGS surveillance globally. While primarily a hardware/minion-based company rather than a surveillance services firm, it is a key adjacent and enabling peer given the Centre's analytical work.
• Big Data Institute (University of Oxford): The Oxford-based research institute housing the Centre's genomic epidemiology work and a leading hub for pathogen genomics and AMR analytics. It is highly comparable as the immediate institutional ecosystem and primary academic counterpart.
• Wellcome Sanger Institute (Pathogen Genomics group): A leading UK genome research institute whose Pathogen Genomics group performs WGS-based surveillance and outbreak analysis very similar to the Centre's remit. It is a broader, established comparator in the same niche, operating from a non-profit but deeply overlapping capability set.

Regional players

• Genomics England: A UK government-backed organisation running large-scale genomic sequencing and data programmes that increasingly extends into infectious disease and pathogen surveillance. It is a same-region peer with comparable genomic capability and a public-good mandate.

Emerging players

• Cergentis: A T2A-evidenced, smaller-scale genomics services and bioinformatics company working in pathogen genomics and surveillance-adjacent assays. It is comparable as a niche, scientific operator competing for similar academic and public-health projects.
• Resistomap: A smaller emerging player focused on environmental and wastewater AMR surveillance analytics, which is an overlapping use case with the Centre's AMR surveillance strategies offering and similarly leverages WGS-based analytics.
• BUGS Bioscience: A smaller emerging pathogen genomics services company providing WGS-based pathogen surveillance and outbreak analysis to public health and academic customers, directly comparable in scale and focus.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat3 records

Key risks5 records

Key highlights4 records

Customer concentration

• Xx.com/TheCGPS
• LinkedInlinkedin.com/company/cgps-uk

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Centre for Genomic Pathogen Surveillance